March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.

The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were as of February 26, 2021:

SHAREHOLDER NUMBER OF SHARES OWNERSHIP % VOTES %
Linc AB 69 920 567 13.1% 13.1%
HBM Healthcare Investments 52 916 667 9.9% 9.9%
Fjärde AP-fonden 52 314 074 9.8% 9.8%
Försäkringsbolaget Avanza Pension 25 330 798 4.8% 4.8%
Handelsbanken Läkemedelsfond 25 000 000 4.7% 4.7%
SEB-Stiftelsen 19 047 617 3.6% 3.6%
SEB Life International 13 927 350 2.6% 2.6%
Nordnet Pensionsförsäkring AB 13 472 878 2.5% 2.5%
SEB Venture Capital 12 994 367 2.4% 2.4%
Stiftelsen Industrifonden 12 865 296 2.4% 2.4%
Bengt Thornberg 12 671 394 2.4% 2.4%
Staffan Rasjö 11 797 670 2.2% 2.2%
S-E-Bankens Utvecklingsstiftelse 10 000 000 1.9% 1.9%
Originat AB 7 000 000 1.3% 1.3%
Rune Pettersson, dödsbo 5 880 486 1.1% 1.1%

 

For more information:
Peter Zerhouni, CEO
Phone: +46 8 122 038 50
E-mail: peter.zerhouni@indexpharma.com

Publication
The information was submitted for publication through the agency of the contact person set out above at 13:45 CET on March 12, 2021.

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The Company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market. Redeye AB with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the Company’s Certified Adviser. For more information, please visit www.indexpharma.com.